キャンバスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/07/07 | 1,012 | 1,033 | 1,001 | 1,018 | +1 | +0.1% | 218,800 |
| 2025/07/04 | 1,025 | 1,043 | 1,012 | 1,017 | -20 | -1.9% | 242,300 |
| 2025/07/03 | 1,017 | 1,037 | 995 | 1,037 | +23 | +2.3% | 283,100 |
| 2025/07/02 | 1,039 | 1,070 | 1,010 | 1,014 | -54 | -5.1% | 480,200 |
| 2025/07/01 | 1,170 | 1,178 | 1,063 | 1,068 | -127 | -10.6% | 859,500 |
| 2025/06/30 | 1,063 | 1,229 | 1,055 | 1,195 | +107 | +9.8% | 1,224,200 |
| 2025/06/27 | 1,100 | 1,128 | 1,053 | 1,088 | -6 | -0.5% | 854,600 |
| 2025/06/26 | 1,058 | 1,142 | 1,057 | 1,094 | +6 | +0.6% | 1,995,500 |
| 2025/06/25 | 1,070 | 1,088 | 1,010 | 1,088 | +150 | +16% | 1,343,600 |
| 2025/06/24 | 939 | 948 | 934 | 938 | +14 | +1.5% | 189,400 |
| 2025/06/23 | 953 | 953 | 909 | 924 | -42 | -4.3% | 430,300 |
| 2025/06/20 | 955 | 1,000 | 952 | 966 | +14 | +1.5% | 471,700 |
| 2025/06/19 | 968 | 996 | 931 | 952 | -7 | -0.7% | 409,700 |
| 2025/06/18 | 962 | 979 | 955 | 959 | ±0 | ±0% | 228,600 |
| 2025/06/17 | 971 | 984 | 953 | 959 | -10 | -1% | 206,300 |
| 2025/06/16 | 931 | 1,020 | 929 | 969 | +34 | +3.6% | 571,800 |
| 2025/06/13 | 972 | 979 | 926 | 935 | -22 | -2.3% | 377,600 |
| 2025/06/12 | 966 | 986 | 950 | 957 | -8 | -0.8% | 290,800 |
| 2025/06/11 | 954 | 989 | 951 | 965 | +11 | +1.2% | 298,500 |
| 2025/06/10 | 949 | 965 | 938 | 954 | +3 | +0.3% | 223,200 |
| 2025/06/09 | 933 | 955 | 925 | 951 | +19 | +2% | 316,400 |
| 2025/06/06 | 940 | 954 | 926 | 932 | -21 | -2.2% | 338,800 |
| 2025/06/05 | 989 | 995 | 947 | 953 | -30 | -3.1% | 441,000 |
| 2025/06/04 | 972 | 1,003 | 964 | 983 | +11 | +1.1% | 352,700 |
| 2025/06/03 | 982 | 991 | 958 | 972 | -3 | -0.3% | 445,700 |
| 2025/06/02 | 1,015 | 1,018 | 951 | 975 | -32 | -3.2% | 561,900 |
| 2025/05/30 | 1,028 | 1,045 | 995 | 1,007 | -26 | -2.5% | 616,200 |
| 2025/05/29 | 1,063 | 1,070 | 1,012 | 1,033 | -38 | -3.5% | 659,400 |
| 2025/05/28 | 1,167 | 1,174 | 1,064 | 1,071 | -99 | -8.5% | 818,000 |
| 2025/05/27 | 1,163 | 1,194 | 1,160 | 1,170 | -23 | -1.9% | 412,900 |
| 2025/05/26 | 1,255 | 1,279 | 1,190 | 1,193 | -88 | -6.9% | 664,300 |
| 2025/05/23 | 1,305 | 1,415 | 1,233 | 1,281 | -1 | -0.1% | 908,600 |
| 2025/05/22 | 1,342 | 1,350 | 1,260 | 1,282 | -120 | -8.6% | 1,114,400 |
| 2025/05/21 | 1,273 | 1,430 | 1,224 | 1,402 | +167 | +13.5% | 1,430,600 |
| 2025/05/20 | 1,150 | 1,282 | 1,130 | 1,235 | +83 | +7.2% | 1,032,900 |
| 2025/05/19 | 1,215 | 1,230 | 1,124 | 1,152 | +72 | +6.7% | 942,900 |
| 2025/05/16 | 1,060 | 1,094 | 1,042 | 1,080 | +33 | +3.2% | 371,600 |
| 2025/05/15 | 1,056 | 1,073 | 1,017 | 1,047 | -7 | -0.7% | 343,400 |
| 2025/05/14 | 1,005 | 1,109 | 960 | 1,054 | +60 | +6% | 899,300 |
| 2025/05/13 | 986 | 1,000 | 976 | 994 | +10 | +1% | 219,800 |
| 2025/05/12 | 1,019 | 1,019 | 980 | 984 | -37 | -3.6% | 244,900 |
| 2025/05/09 | 1,003 | 1,041 | 998 | 1,021 | +13 | +1.3% | 176,000 |
| 2025/05/08 | 1,021 | 1,034 | 1,008 | 1,008 | -9 | -0.9% | 123,800 |
| 2025/05/07 | 1,018 | 1,031 | 1,012 | 1,017 | -19 | -1.8% | 189,100 |
| 2025/05/02 | 1,054 | 1,066 | 1,022 | 1,036 | -24 | -2.3% | 219,200 |
| 2025/05/01 | 1,011 | 1,073 | 1,011 | 1,060 | +38 | +3.7% | 364,200 |
| 2025/04/30 | 1,027 | 1,045 | 1,008 | 1,022 | -8 | -0.8% | 210,500 |
| 2025/04/28 | 1,006 | 1,030 | 995 | 1,030 | +18 | +1.8% | 198,400 |
| 2025/04/25 | 1,019 | 1,033 | 1,008 | 1,012 | -9 | -0.9% | 225,200 |
| 2025/04/24 | 1,021 | 1,040 | 1,008 | 1,021 | +8 | +0.8% | 174,400 |
1～
50
件表示中 / 3736件
類似銘柄と比較する
現在ご覧いただいている「ＣＡＮＢＡＳ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＣＡＮＢＡＳ | 101,800円 | - | - | 0.00% | - | 6.72倍 |
|
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索 |
| ミズホメディ | 141,100円 | -20.7% | -41.2% | 6.02% | 12.03倍 | 1.55倍 |
|
体外検査薬専業、感染症抗体、遺伝子検査機器、試薬開発。新型コロナで急成長、妊娠検査薬も |
| アンジェス | 5,700円 | +110.0% | - | 0.00% | - | 9.81倍 |
|
大阪大医学部、森下竜一教授創業の創薬ベンチャー。遺伝子治療薬を核に核酸医薬など開発多彩 |
| 扶桑薬 | 208,800円 | +1.6% | -12.7% | 4.31% | 7.75倍 | 0.54倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開 |
| ステムリム | 30,200円 | - | - | 0.00% | - | 2.78倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
市場注目の銘柄
チャート関連のコラム
